Two prominent shareholder advisory firms are urging Regeneron Pharmaceuticals (REGN) shareholders to remove a director who is on the compensation committee, citing concerns over “problematic” pay practices and “excessive” awards given to the top two executives.
In separate investor alerts, the advisory firms argue the Regeneron board has showered chief executive officer Leonard Schleifer and president and chief scientific officer George Yancopoulos with upfront performance stock units worth $130 million over five years, rather than annual grants. This approach may lock in executives, but the firms say it also robs the board of flexibility if job performance changes during that time.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
